These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21537073)

  • 41. Management of hepatitis B in pregnancy: weighing the options.
    Tran TT
    Cleve Clin J Med; 2009 May; 76 Suppl 3():S25-9. PubMed ID: 19465706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
    Lu HY; Zhuang LW; Yu YY; Si CW
    J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of high viral hepatitis B virus DNA loads on vertical transmission of hepatitis B virus in late-pregnant women].
    Yang S; Liu M; Wang L
    Zhonghua Fu Chan Ke Za Zhi; 2008 May; 43(5):329-31. PubMed ID: 18953863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries.
    Li W; Jia L; Zhao X; Wu X; Tang H
    BMC Gastroenterol; 2018 Aug; 18(1):121. PubMed ID: 30071845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary study on the efficacy and safety of lamivudine and interferon alpha therapy in decreasing serum HBV DNA level in HBV positive transgenic mice during pregnancy.
    Li D; Xu DZ; Choi BC; Men K; Zhang JX; Lei XY; Yan YP
    J Med Virol; 2005 Jun; 76(2):203-7. PubMed ID: 15834875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients during Pregnancy and Post-Partum Follow-Up.
    Virine B; Osiowy C; Gao S; Wang T; Castillo E; Martin SR; Lee SS; Simmonds K; van Marle G; Coffin CS
    PLoS One; 2015; 10(10):e0140070. PubMed ID: 26474400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
    Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.
    van Zonneveld M; van Nunen AB; Niesters HG; de Man RA; Schalm SW; Janssen HL
    J Viral Hepat; 2003 Jul; 10(4):294-7. PubMed ID: 12823596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interruption of HBV intrauterine transmission: a clinical study.
    Li XM; Yang YB; Hou HY; Shi ZJ; Shen HM; Teng BQ; Li AM; Shi MF; Zou L
    World J Gastroenterol; 2003 Jul; 9(7):1501-3. PubMed ID: 12854150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.
    Brown RS; McMahon BJ; Lok AS; Wong JB; Ahmed AT; Mouchli MA; Wang Z; Prokop LJ; Murad MH; Mohammed K
    Hepatology; 2016 Jan; 63(1):319-33. PubMed ID: 26565396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region.
    Samadi Kochaksaraei G; Castillo E; Osman M; Simmonds K; Scott AN; Oshiomogho JI; Lee SS; Myers RP; Martin SR; Coffin CS
    J Viral Hepat; 2016 Jan; 23(1):15-22. PubMed ID: 26192022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.
    Jourdain G; Ngo-Giang-Huong N; Cressey TR; Hua L; Harrison L; Tierney C; Salvadori N; Decker L; Traisathit P; Sirirungsi W; Khamduang W; Bowonwatanuwong C; Puthanakit T; Siberry GK; Watts DH; Murphy TV; Achalapong J; Hongsiriwon S; Klinbuayaem V; Thongsawat S; Chung RT; Pol S; Chotivanich N
    BMC Infect Dis; 2016 Aug; 16():393. PubMed ID: 27506549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates.
    Zhang L; Gui XE; Wang B; Fan JY; Cao Q; Mullane K; Liang XL
    BMC Infect Dis; 2016 Aug; 16(1):408. PubMed ID: 27515176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.
    Greenup AJ; Tan PK; Nguyen V; Glass A; Davison S; Chatterjee U; Holdaway S; Samarasinghe D; Jackson K; Locarnini SA; Levy MT
    J Hepatol; 2014 Sep; 61(3):502-7. PubMed ID: 24801414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China.
    Lu Y; Zhu FC; Liu JX; Zhai XJ; Chang ZJ; Yan L; Wei KP; Zhang X; Zhuang H; Li J
    Vaccine; 2017 Dec; 35(48 Pt B):6627-6633. PubMed ID: 29079104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.